Skip to content
ClinCalc Pro
Menu
Electrolyte Pregnancy: Calcium passes across the placental barrier and its concentration in foetal blood is higher than in maternal blood. Should not be used during pregnancy unless the clinical condition of the woman requires it; the dose must be carefully calculated and serum calcium regularly evaluated to avoid hypercalcaemia, which may be deleterious for the foetus. Breast-feeding: calcium is excreted in breast milk — decide whether to discontinue breast-feeding or the treatment, taking account of the benefit of each.

Calcium Gluconate 10%

Brand names: Calcium Gluconate 10% Injection

Used in: Acute Kidney Injury Hyperkalaemia

Calcium gluconate 10% is an intravenous calcium salt used in emergencies for cardiac membrane protection in severe hyperkalaemia, symptomatic hypocalcaemia, and as an antidote in magnesium or calcium-channel-blocker toxicity and hydrofluoric acid burns.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Acute symptomatic hypocalcaemia (adults with normal renal function): 10-20 mL of Calcium Gluconate 10% (corresponding to 2.23-4.46 mmol calcium) undiluted as a slow intravenous injection over 10 minutes, OR the same 10-20 mL diluted in 50-100 mL of glucose 5% or sodium chloride 0.9% as a slow intravenous infusion over 10 minutes — both with plasma-calcium and ECG monitoring
Route: Slow intravenous injection (undiluted) or slow intravenous infusion after dilution in glucose 5% or sodium chloride 0.9%
Frequency: If necessary the dose can be repeated depending on the clinical condition; subsequent doses adjusted according to the actual serum calcium level
OTHER ADULT INDICATIONS IN THE SAME SPC. Acute severe hyperkalaemia with or without ECG changes (serum potassium above 6.5 mmol/L): 30 mL of Calcium Gluconate 10% (6.69 mmol calcium) undiluted as a slow intravenous injection over 10 minutes; further doses can be considered after 5 minutes if needed until ECG improvement is achieved. Cardiac arrest due to hyperkalaemia: 30 mL of Calcium Gluconate 10% (6.69 mmol calcium) undiluted as a RAPID intravenous injection, repeatable if return of spontaneous circulation is not achieved within 5-10 minutes or if resuscitation is prolonged (onset of action within 3 minutes, duration 30-60 minutes). Normal plasma calcium is 2.25-2.75 mmol/L (4.5-5.5 mEq/L) in adults; treatment aims to restore or maintain this and serum calcium must be monitored closely. If plasma calcium exceeds 2.75 mmol/L, or 24-hour urinary calcium excretion exceeds 5 mg/kg, stop treatment immediately as cardiac arrhythmias may occur. SALT STRENGTH WARNING: 10 mL of calcium gluconate 10% contains 2.23 mmol calcium whereas 10 mL of calcium chloride 10% contains 6.8 mmol calcium — the difference must be accounted for to avoid medication errors. Must NOT be mixed with or given through the same line as sodium bicarbonate (risk of precipitation), or with phosphate-containing solutions. PAEDIATRIC dosing in this SPC is expressed in mL/kg of the 10% solution and mmol/kg (not mg/kg), so no structured per-kg mg dose is given here. Slow IV injection for urgent correction of acute symptomatic hypocalcaemia: neonates (0-27 days) a single dose of 1 mL/kg (0.22 mmol calcium/kg) undiluted over 5-10 minutes (lower doses of 0.5 mL/kg, 0.11 mmol/kg, have also been shown effective; may be diluted 1:1 or 1:5 in glucose 5%; rate not to exceed 0.22 mmol calcium/min); children 28 days to <18 years a single dose of 0.3-0.6 mL/kg (0.07-0.13 mmol calcium/kg) undiluted over 5-10 minutes (may be diluted 1:5; rate not to exceed 0.22 mmol calcium/min). Slow continuous infusion: neonates initially 0.2-0.3 mL/kg/hour (0.04-0.07 mmol calcium/kg) diluted 1:10 — an initial rate of 0.1 mL/kg/hour (0.02 mmol/kg/hour) has also been effective — with a maximum recommended rate in neonates of 0.1 mL/kg/hour (0.022 mmol/kg/hour); children 28 days to <18 years initially 0.08 mL/kg/hour (0.02 mmol calcium/kg/hour) diluted 1:10, maximum recommended rate 0.2 mL/kg/hour (0.045 mmol/kg/hour). A maximum dose of 1 mL/kg (0.22 mmol calcium/kg) is recommended in children 0 to <18 years because of the risk of aluminium exposure. For hyperkalaemia in children the cardiac arrest regimen should be followed: neonates 0.5 mL/kg (0.11 mmol calcium/kg) undiluted over 5-10 minutes given centrally where possible (if no central access, dilute five-fold with sodium chloride 0.9%), repeatable if ECG changes persist after 5-10 minutes; children 28 days to <18 years 0.5 mL/kg (0.11 mmol calcium/kg) — the remainder of this sentence is truncated in the fetched source. Verify all paediatric dosing against a children's formulary. NOTE: the US openFDA label fetched (Calcium Gluconate in Sodium Chloride Injection) uses different units and different figures (adults 1,000-2,000 mg initially, repeatable every 6 hours, continuous infusion 5.4-21.5 mg/kg/hour) — not used here; the UK SPC takes precedence.

Dose adjustments

Renal

No numeric adjustment stated in the UK SPC. Section 4.4: renal impairment may be associated with hypercalcaemia and secondary hyperparathyroidism, so in renal impairment parenteral calcium should be given only after careful assessment of the indication and the calcium-phosphate balance should be monitored; repeated or prolonged treatment is contraindicated in impaired renal function because of aluminium exposure. In severe renal insufficiency and renal failure, appropriate blood purification methods (haemodialysis or peritoneal dialysis) should be considered (text truncated in source).

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients
  • Hypercalcaemia (e.g. hyperparathyroidism, hypervitaminosis D, neoplastic disease with decalcification of bone, renal insufficiency, immobilisation osteoporosis, sarcoidosis, milk-alkali syndrome) and hypercalciuria
  • Poisoning with cardiac glycosides, and patients receiving cardiac glycosides — the only exception may be where intravenous calcium is imperative for severe hypocalcaemic symptoms or acute severe hyperkalaemia placing the patient at immediate vital risk, if safer alternatives are unavailable and the oral route is not possible
  • Co-administration with ceftriaxone in premature newborns up to a corrected age of 41 weeks and in full-term newborns up to 28 days of age (risk of ceftriaxone-calcium precipitation)
  • Repeated or prolonged treatment in children under 18 years and in those with impaired renal function, due to the risk of aluminium exposure — the product is indicated for acute, symptomatic treatment only and must not be used to prepare total parenteral nutrition

Side effects

  • Cardiac: bradycardia, cardiac arrhythmia, cardiac arrest, syncope (frequency not known)
  • Vascular: hypotension, vasodilatation, circulatory collapse (possibly fatal), flushing (frequency not known)
  • Administration-site: calcinosis cutis due to extravasation, possibly followed by skin ablation and necrosis, with cardiovascular and other systemic effects
  • Nausea and vomiting; heat sensations and sweating
  • Severe and in some cases fatal reactions following intravenous ceftriaxone plus calcium salt in preterm and full-term newborns aged <28 days (rare); aluminium accumulation and toxicity with repeated or prolonged treatment (microcytic anaemia, osteopenia, fractures, rickets, impaired bone mineralisation, neurotoxicity, hepatotoxicity)

Interactions

  • Ceftriaxone — contraindicated in neonates as above; must not be mixed or co-administered (see sections 4.3 and 4.4)
  • Cardiac glycosides (e.g. digoxin) — contraindicated in patients receiving them; if intravenous calcium is exceptionally necessary, adequate cardiac monitoring is mandatory and emergency treatment for serious arrhythmias must be available, as rapid calcium administration may precipitate myocardial digoxin toxicity
  • Epinephrine (adrenaline) — calcium salts should be used with caution in patients receiving epinephrine (section 4.4)
  • Sodium bicarbonate — must not be mixed with, or administered through the same intravenous line as, calcium gluconate due to the risk of precipitation; the same applies to phosphate-containing solutions

Clinical monograph

How it works

Calcium ions antagonise the membrane effects of hyperkalaemia by restoring the resting potential and stabilise myocardial and neuromuscular excitability.

Prescribing in practice

  • It provides less elemental calcium per volume than calcium chloride, so the salts are not interchangeable and the correct salt and strength must be confirmed for the indication.
  • It is less irritant than calcium chloride and so is often preferred for peripheral administration, but extravasation can still cause tissue injury and it should be given slowly with cardiac monitoring.
  • Avoid co-administration with bicarbonate- or phosphate-containing fluids, which precipitate, and use caution in patients taking digoxin.

Monitoring

Monitor ECG continuously alongside serum calcium and potassium, and watch the cannula site during administration.

Counselling the patient

  • Keep calcium-containing and bicarbonate/phosphate infusions in separate lines.
  • In hyperkalaemia calcium only buys time; potassium-lowering measures must follow.
  • Distinguish clearly between calcium gluconate and calcium chloride preparations.

Evidence & guidelines

Calcium gluconate for cardioprotection in hyperkalaemia is recommended in UK renal association and Resuscitation Council UK hyperkalaemia guidance.

Reference: UK Renal Association Hyperkalaemia Guidelines 2020; NICE; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

Calcium Gluconate 10% is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.